“…The GDI has been used as an outcome measure to study gait in several conditions such as: CP ( Schwartz and Rozumalski, 2008 ; Molloy et al, 2010 ; Cimolin et al, 2011 ; Sagawa et al, 2013 ; Massaad et al, 2014 ; Wilson et al, 2015 ; Malt et al, 2016 ; Ito et al, 2019 ; Rasmussen et al, 2019 ), post-stroke hemiparetic gait ( Correa et al, 2017 ; Guzik and Drużbicki, 2020 ), Duchenne muscular dystrophy ( Sienko Thomas et al, 2010 ), Parkinson’s disease ( Galli et al, 2012 ; Speciali et al, 2013 ), arthritis ( Broström et al, 2013 ; Esbjörnsson et al, 2014 ; Rosenlund et al, 2016 ; Kobsar et al, 2019 ; Bazarnik-Mucha et al, 2020 ), lower limb amputations ( Eshraghi et al, 2014 ; Kark et al, 2016 ), degenerative spinal pathologies ( Mar et al, 2019 ; Trivedi et al, 2021 ; Zhou et al, 2021 ), diverse genetic ( Ito et al, 2020 ; Mindler et al, 2020 ) and congenital disorders ( Eriksson et al, 2015 ; Garman et al, 2019 ), and even the effect of the COVID-19 on physical function ( Ito et al, 2021 ), among others. A recently published article by Hwang et al (2021) used the GDI as a way to quantify and characterize gait patterns in ambulatory children and adolescents with transverse myelitis, whose gait showed moderate kinematic deviations from normal gait pattern.…”